|
Volume 15, Issue 1 (January 2013) 15, 83–84; 10.1038/aja.2012.133
Identification, characterization and targeting of Docetaxel-resistant prostate cancer cells
Tanya I Stoyanova1 and Andrew S Goldstein2,3,4,5
1 Departments of Microbiology Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA
2 Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA
3 Urology, University of California, Los Angeles, CA 90095, USA
4 Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
5 Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095, USA
Correspondence: Dr AS Goldstein, (AGoldstein@mednet.ucla.edu)
published online: 3 December 2012
| Abstract |
|
Men with castration-resistant prostate cancer exhibit resistance to chemotherapeutic agents such as Docetaxel. Defining the mechanisms of resistance to Docetaxel is critical for treating advanced disease. In a new study, Carlos Cordon-Cardo and colleagues determine that Docetaxel-resistant prostate cancer cells rely on the Notch and Hedgehog signaling pathways for their survival. These findings provide a rationale for the inhibition of Notch and Hedgehog pathways in Docetaxel-resistant prostate cancer. The authors demonstrate that Docetaxel-resistant cells can propagate tumors and may exist prior to treatment, suggesting that Notch/Hedgehog pathway inhibition in combination with Docetaxel may prevent treatment-resistance.
PDF |
PDF |
|
| |
| Browse: 3935 |
|
